CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended		100 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash Flows From Operating Activities:
Net loss	$ (16,225)	$ (18,697)	$ (187,402)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	28		94
Distribution of non-cash items	84		84
Loss on disposal of property and equipment			2
Stock-based compensation expense	1,264	1,257	11,362
Accretion of discount/premium on investment securities	24	37	(3)
Purchased in-process research and development			28,157
Change in fair value of derivative instruments-warrants	(223)	1,093	(3,993)
Changes in operating assets and liabilities:
Security deposit			(20)
Accounts payable and accrued expenses	(3,011)	700	10,540
Prepaid expenses and other current assets	(1,860)	(27)	(5,578)
Total Adjustments	(3,694)	3,060	40,645
Net Cash Used in Operating Activities	(19,919)	(15,637)	(146,757)
Cash Flows From Investing Activities:
Net cash paid on Exchange Transaction			(155)
Loans to related parties		(270)	(3,576)
Sale/(purchases) of available-for-sale securities		8,000	(50,000)
Additions to property and equipment	(28)	(78)	(685)
Repayment on ContraVir loan receivable	455		455
Net Cash (Used in)/Provided by Investing Activities	427	7,652	(53,961)
Cash Flows From Financing Activities:
Issuance of common stock pursuant to controlled equity sales agreement	22,606	4,671	233,774
Issuance of common stock of ContraVir	3,224		3,224
Fees and expenses-combined	(639)	(140)	(12,985)
Proceeds from exercise of stock warrants			415
Proceeds from exercise of stock options	36	105	155
Distribution associated with ContraVir Spinoff	(3,230)		(3,230)
Net Cash Provided by Financing Activities	21,997	4,636	221,353
Net increase/(decrease) in cash and cash equivalents	2,505	(3,349)	20,635
Cash and cash equivalents at beginning of period	18,130	12,416
Cash and cash equivalents at end of period	20,635	9,067	20,635
Supplementary disclosure of cash flow information:
Cash paid for taxes	30	18	251
Supplementary disclosure of non-cash investing and financing activities:
Value of warrants classified as derivative liability-net			5,304
Value of common stock issued to induce stockholders to extend lock-up agreements			3,235
Recapitalization of Synergy		$ 4,904	$ 4,904